Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069832 | 1.00 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13429861 | 0.80 | CYP11B1 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL9930356 | 0.77 | HDAC1 (0.34) | SRD5A1AR | |
| SCHEMBL9930190 | 0.75 | CYP3A4 (0.46) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL9091469 | 0.75 | KCNH2 (0.54) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL13429859 | 0.75 | KCNH2 (0.54) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14069498 | 0.75 | KCNH2 (0.54) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14069834 | 0.75 | CYP3A4 (0.46) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL9090163 | 0.75 | KCNH2 (0.54) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL14069890 | 0.69 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | CYP11B2 429/4885CYP11B1 458/4885CYP1A2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.